GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViroGates A/S (OCSE:VIRO) » Definitions » Valuation Rank

ViroGates A/S (OCSE:VIRO) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is ViroGates A/S Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


ViroGates A/S Valuation Rank Related Terms

Thank you for viewing the detailed overview of ViroGates A/S's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


ViroGates A/S (OCSE:VIRO) Business Description

Traded in Other Exchanges
N/A
Address
Banevaenget 13, Birkerod, DNK, DK-3460
ViroGates A/S is a life science company that develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular, to make a clinical decision on hospitalization or discharge of emergency patients. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, and cancer. It has developed a product line called suPARnostic to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision-making.